Table 3 Baseline characteristics of patients with ulcerative colitis in the validation cohort according to one-year treatment outcome level
Patient groups | Mild N = 36 | Moderate N = 31 | Severe N = 22 |
|---|---|---|---|
Age med (IQR) | 36 (24–49) | 30 (24–41) | 26 (22–47) |
Sex | |||
Female | 17 (47%) | 8 (26%) | 10 (46%) |
Male | 19 (53%) | 23 (74%) | 12 (54%) |
Colonic area involved | |||
Proctitis | 5 (14%) | 1 (3%) | 1 (4%) |
Left side | 25 (69%) | 18 (58%) | 10 (46%) |
Extensive | 6 (17%) | 12 (39%) | 11 (50%) |
Smoking | 28 | 21 | 12 |
Current smoker | 1 (4%) | 2 (10%) | 1 (8%) |
Non-smoker | 27 (96%) | 19 (90%) | 11 (92%) |
Mucosal TNF* | 8800 (6100–12,800) | 10,500 (7400–13,200) | 17,400 (15100–26,800) |
UCDAI med (IQR)* at debut | 7 (5–9) | 9 (8–11) | 10 (7–11) |
Calprotectin med (IQR)* | 570 (200–970) | 1000 (340–2000) | 1100 (830–1400) |
RHI med (IQR)* | 6 (2–10) | 6 (4–11) | 14 (9–27) |
UCCS score 1-year med (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–8) |
Calprotectin 1-year med (IQR) | 40 (25–94) | 50 (0–140) | 25 (20–60) |